Form 4: Tempest Therapeutics Corporate Controller Acquires Additional Shares

Justin Trojanowski, Corporate Controller of Tempest Therapeutics, recently purchased 7,500 shares of TPST common stock at $2.16 per share, increasing his total holdings.

Summary

• On June 28, 2024, Justin Trojanowski, the Corporate Controller of Tempest Therapeutics, acquired 7,500 shares of common stock.
• The purchase price was $2.16 per share.
• Following the transaction, Trojanowski directly owns 22,168 shares of Tempest Therapeutics.
• This includes 14,668 shares acquired under the Issuer's stock purchase plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The purchase of shares by a company officer is generally viewed as a positive sign, but without additional context, it's difficult to gauge the significance.

Positives

• The purchase of shares by a company officer can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as an indicator of management's sentiment about the company's prospects. It can be compared to other insider transactions within the biotechnology industry to gauge overall confidence.

Comparison to Industry Standards

• Comparing this transaction to similar insider purchases in comparable biotech companies would provide context.
• For example, if executives at companies like Amgen or Gilead Sciences were also making open market purchases, it could signal broader optimism in the sector.
• Conversely, a lack of insider buying across the industry might suggest caution.

Stakeholder Impact

• Shareholders may view the insider purchase positively.
• Employees may see it as a sign of confidence in the company's future.

Key Dates